Therefore, osimertinib is suggested as a preferred agent for treating advanced NSCLC patients with secondary T790M mutations after they experience acquired resistance to prior 1st- and 2nd-generation EGFR-TKI therapies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.